A randomised phase II trial of personalized peptide vaccination plus "Keppuchikuoto" vs personalized peptide vaccination alone for non small cell lung cancer patients - A randomised phase II trial of peptide vaccination with "keppuchikuoto" for non samll cell lung cancer patients

Kurume Unversity Cancer Vaccine Center0 个研究点目标入组 60 人开始时间: 2014年9月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The following patients must be excluded: 1) Patients with severe underlying diseases / conditions(active and severe infectious diseases, circulatory diseases, respiratory diseases, renal diseases, immunodeficiencies, disturbance of coagulation, et al. Respiratory diseases are pulmonary damage, such as interstitial pneumonia and pneumoconiosis). 2) Active double cancer(synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ(lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 3) Patients with the past history of severe allergic reactions. 4) (Females)Pregnant or nursing patients. Patients desiring future fertility. (Males)Patients who do not sccept contraception from the 1st vaccination until 70 days after the last vaccination. 5) Patients who has taken Keppuchikuoto. 6) Patients who has taken Bevacizumab.(Participation is made possible when four or more weeks have passed from the last medication to an examination opening day.) 7) Patients who are judged inappropriate for entry to this clinical trial by doctors.

发起方

Kurume Unversity Cancer Vaccine Center